|
 The once-weekly drug belongs to a family of diabetes treatments
called GLP-1 receptor agonists, which includes Novo Nordisk's widely
used daily treatment Victoza. They act like GLP-1, a natural
hormone, in prodding the body to release insulin when patients eat.
Trulicity (dulaglutide) can be taken any time of day, with or
without meals, and either by itself or with other treatments for the
most common form of diabetes, which is highly linked to obesity. It
received U.S. marketing approval on Sept. 18.
Like other diabetes drugs, including insulin, Trulicity can cause
hypoglycemia, a potentially dangerous decline in blood sugar that
can cause fainting, nausea and other symptoms.
(Reporting by Ransdell Pierson; Editing by Cynthia Osterman)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
